Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

735 Features
Imaging Biomarkers

11 Nov 10

Large pharma has been seeking new biomarkers for years – all part of their drug discovery process, but often only as an afterthought in the development process. That’s changed over recent years, but by-and-large the bulk of biomarker work remains in the hands of small -to -medium-sized companies whose focused approach is more attuned to biomarkers being a major element of a final product.
Daniel Reinhold-Shor

BrightTALKâ„¢ Digital Marketing and Pharma Summit

11 Nov 10

As patients and prescribers increasingly move online for their information, how can pharma engage these audiences by incorporating digital marketing into their current plans?
Mike Wood

The Pharma-Nutrition interface: the gap is narrowing

04 Nov 10

Most pharmacologists will acknowledge that nutrition is important for good health and well-being, however, at the same time it is also considered to be a chemical nightmare with unknown effects. This has not always been the case, in the past connections between pharmacology and nutrition has been more intimate, as Hippocrates once stated, ‘‘Let food be thy medicine and let medicine be thy food.
Johan Garssen, PhD, Conference Chairman

The Future of Pharma is Asia

03 Nov 10

Reshaping the pharmaceutical industry's quality standards is currently the top priority for the Chinese government. Earlier announcements by its Ministry of Health to issue new tougher Good Manufacturing Processes (GMP) standards for medical products comes at the right time as current regulations do not meet international standards which result in poor performance by Chinese companies in the international market.
Emma Naylor

Quick Look: Probiotics

27 Oct 10

Now more than ever, alternative science and holistic remedies are playing a role in our lifestyles. But is that right? Over the past year, we've reported on everything from homeopathy to hypnotherapy. Importantly, we've differentiated between those approaches with at least a modicum of evidence to support them, and those without almost any at all. Yet in contrast to homeopathy, perhaps it can be said that our next target has at least a little science to support it.
Max Golby

Manufacturing Safety Raises Concern

20 Oct 10

Last week Pharmaceutical heads met as a result of a drugs recall after a pill mix up of breast cancer pills. The drug, Fresenius Kabi’s Anastrozole, was made by the German company’s subsidiary in India. The ingredient mix up led to the voluntary recall of 7,192 bottles, each containing 30 tablets.
Emma Naylor- NG Online

Focus on HealthcarePromotions.co.uk

19 Oct 10

HealthcarePromotions.co.uk was created to provide UK healthcare professionals and students with a website for all their health promotion resources and news.
James Morgan, Director Healthcare Promotions Ltd

NHS Reform - The Dangers Ahead

18 Oct 10

As Republican Congressmen line up to attack Barack Obama’s landmark U.S. healthcare reforms ahead of next month’s mid-term elections, reforms on this side of the Atlantic are receiving equally forceful criticism.
Max Golby

Cyber Branding & Hyper Visibility

18 Oct 10

Out there on the branding battlefields its simply do or die as brand images are either hyper visible or mortally lost in oblivion. Commanding success for any idea on the global scene demands universal access on e-commerce that is only deliverable by a cyber name identity, as it's the only key to open the site.
Naseem Javed

Arabian Adventures

08 Oct 10

The Kingdom of Saudi Arabia provides a new opportunity for clinical research, and can open doors to untapped populations, explains Rani Abraham at ClinTec International
Rani Abraham - ClinTec International

Pharmaceutical Question Time

08 Oct 10

With access, cost and quality concerns plaguing pharmaceutical delivery systems both in the US as well as globally, the Next Generation Pharmaceutical Drug Discovery committee has been formed to confront, assess and deliver new strategies to secure the future of the industry.
Emma Naylor

The Cost of CV Writing Services

29 Sep 10

If you have been looking around for a CV writing service you will have noticed that prices vary considerably and may be wondering why. The CV & Interview Advisors (that’s us) were one of the early entrants into the world of CV writing and have been around for many years.
Matt Craven

The Merits of Free CV appraisals

29 Sep 10

Over the last few years, many companies have started to offer CV appraisals to the extent that the market is now flooded with offers of free advice. I remember the days when we and one or two other CV writing companies offered such a service and it became a very effective way of building relationships with customers and strutting our expertise on all things CV related.
Matt Craven

Should a CV include a Personal Profile – the current view!

29 Sep 10

There has been some conjecture amongst professionals regarding the merits of a personal profile on a CV. This conjecture stems from the fact that many job seekers fill there personal profiles with irrelevant and mostly clichéd information.
Matt Craven

Freelancers & Contractors - how to write a CV that isn’t 6 pages long!

29 Sep 10

In my capacity as a Career Consultant, I have worked closely with freelancers & contractors for many years and two challenges keep rearing their ugly head: Firstly, how does a freelancer write a CV that isn’t six pages long; and secondly, what happens if you want to apply for a role that draws upon skills gained in a contract that isn’t the most recent piece of work that you have done.
Matt Craven

UK Science Funding: Doing More With Less

24 Sep 10

In a climate of fiscal hardship, everybody has a special case to plead. Indeed, when the funding scalpel is out, every department and almost every recipient of public sector funds has a special tale to tell. The truth is, science funding really is that important.
Max Golby

Calling all health practitioners.... Have you ever written anything about your profession?

20 Sep 10

If you have written material for a journal like this one, or a book, we may be holding monies due to you.
James Davis

US Prescription Drug Use- The Rise and Rise

16 Sep 10

As healthcare innovation produces new treatments, and new information delivers increased awareness, a substantial rise in prescription drug use is only to be expected. For the most part, this can largely be seen as a positive development.
Max Golby

Stem Cell Research: The Politics of Science

09 Sep 10

Potentially lifesaving science should not be marginalized to the status of a political football. Yet for so many years in the United States, that’s exactly what stem cell science has become.
Max Golby

Career Opportunities in Clinical Drug Research

07 Sep 10

A new book by Rebecca J. Anderson
Mike Wood

Pharma to Make the Private Public

06 Sep 10

Last week, leaders from companies like AstraZeneca, GlaxoSmithKline, Pfizer and Roche met in Vienna in a closed meeting to discuss the future of the pharma industry. Fears of layoffs at pharmaceutical companies are once again dominating the news, but could there be a less painful way to save money?
Emma Naylor

Quick Look: Dementia

02 Sep 10

Even in the good years, mental health budgets were seldom in line with what experts expected or deemed necessary. Thus, in times of budget deficits and scathing public expenditure cuts, the worry becomes even greater. For those that care most about the health service then, the Coalition government's decision to ring fence healthcare spending has been largely applauded.
Max Golby

PFI Hospitals: Reality Hits

25 Aug 10

Originally born under the Conservatives, but fully evolved under Labour, Private Finance Initiatives (PFIs) essentially offered the NHS an alternative way of paying for new hospitals and renovations at a time when public capital was said to be limited.
Max Golby

Hospitality or Bribery? U.S. Pharma under the Spotlight

23 Aug 10

While long prohibited under UK ABPI regulations, if you’ve worked in the world of big pharma in the U.S., you’ll have seen it all a hundred times. A drugs company sponsors a medical conference, they pay for the meals and flights of the delegates and they hand them all a goodie bag as they leave.
Max Golby

NHS Reform

30 Jul 10

We have a fundamental problem with our health service. It's bloated, it's weighed down in bureaucracy and it's terribly inefficient. That's if you believe the diagnosis of our health service by the new Health Secretary, Andrew Lansley.
Max Golby

Worst Possible Interview Mistakes

23 Jul 10

If the nation’s recruiters received a pound for every time they’d interviewed a candidate that looked good on paper but disappointed in practice, there’d currently be an awful lot of recruiters in the process of relocating to the Caribbean.
Max Golby / Mike Wood

Pharma ‘HTS’ the Mark with Screening

22 Jul 10

Back in May, it was announced that new stem cell research would reduce the need for animal testing. Now, we are really beginning to see the benefits of groundbreaking science that is not reliant on out dated methods of testing.
Emma Naylor

Increasing numbers of deaths from malignant melanoma should be prevented by early detection and protection from ultraviolet rays

20 Jul 10

Skin cancers come in various forms but the type which causes most fear is the malignant melanoma, derived from the pigment-forming cells of the skin or melanocytes.
Dr Laurence Lever

The Research Revolution

19 Jul 10

During a time of major economic downturn, there are few industries that can be said to be truly ‘recession proof’. Yet for years now, big pharma has largely been seen as precisely that. After all, no matter dire the markets, and no matter how low consumer confidence plummets, there is always a demand for healthcare.
Max Golby

NHS Targets

25 Jun 10

In areas such as competition policy and choice in the NHS, there could be said to be much correlation between the approaches of both governments past and present. Yet in other key areas of policy, there are unquestionably examples of ideological, or at least philosophical, differences in outlook. Or at least in theory.
Max Golby

Advertising